Affiliation:
1. Systems Immunology Department Weisman Institute of Science Rehovot Israel
2. School of Medicine Paris‐Saclay University Le Kremlin‐Bicêtre France
3. Microbiota & Cancer Division DKFZ Heidelberg Germany
Abstract
AbstractThe microbial community of the gut, collectively termed the gut microbiota, modulates both host metabolism and disease development in a variety of clinical contexts. The microbiota can have detrimental effects and be involved in disease development and progression, but it can also offer benefits to the host. This has led in the last years to the development of different therapeutic strategies targeting the microbiota. In this review, we will focus on one of these strategies that involve the use of engineered bacteria to modulate gut microbiota in the treatment of metabolic disorders. We will discuss the recent developments and challenges in the use of these bacterial strains with an emphasis on their use for the treatment of metabolic diseases.
Funder
H2020 European Research Council
Israel Science Foundation
Minerva Foundation
Garvan Institute of Medical Research
Mark Foundation For Cancer Research
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献